{"entity":{"type":"insider","cik":"0001607714","url":"/insider/0001607714","json_url":"/insider/0001607714.json","name":"Guerin Mark Patrick","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":5,"first":"2017-04-28","last":"2021-02-17","span_basis":"filed_date"},"name_variants":[{"name":"Guerin Mark Patrick","source":"filing","n_filings":5,"first_seen":"2017-04-28","last_seen":"2021-02-17"}],"transactions":[{"id":4628435,"accession":"0001179110-21-001784","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-21-001784","line_url":"/filing/0001179110-21-001784#line-1","is_derivative":false,"issuer_cik":"0001130598","issuer_name":"Onconova Therapeutics, Inc.","issuer_ticker":"ONTX","issuer_name_source":null,"issuer_url":"/issuer/0001130598","owner_cik":"0001607714","owner_name":"Guerin Mark Patrick","owner_url":"/insider/0001607714","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":15000.0,"total_display":"15,000.00","shares_owned_after":145213.0,"shares_owned_after_display":"145,213","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-16","filed_date":"2021-02-17","scope":"insider"},{"id":3054460,"accession":"0001179110-20-011470","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-20-011470","line_url":"/filing/0001179110-20-011470#line-2","is_derivative":false,"issuer_cik":"0001130598","issuer_name":"Onconova Therapeutics, Inc.","issuer_ticker":"ONTX","issuer_name_source":null,"issuer_url":"/issuer/0001130598","owner_cik":"0001607714","owner_name":"Guerin Mark Patrick","owner_url":"/insider/0001607714","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4614.0,"shares_display":"4,614","price_per_share":0.26,"price_display":"0.26","price_state":"stated","total_value":1199.64,"total_display":"1,199.64","shares_owned_after":130213.0,"shares_owned_after_display":"130,213","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-27","filed_date":"2020-11-30","scope":"insider"},{"id":3054450,"accession":"0001179110-20-011470","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-20-011470","line_url":"/filing/0001179110-20-011470#line-1","is_derivative":false,"issuer_cik":"0001130598","issuer_name":"Onconova Therapeutics, Inc.","issuer_ticker":"ONTX","issuer_name_source":null,"issuer_url":"/issuer/0001130598","owner_cik":"0001607714","owner_name":"Guerin Mark Patrick","owner_url":"/insider/0001607714","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16755.0,"shares_display":"16,755","price_per_share":0.26,"price_display":"0.26","price_state":"stated","total_value":4356.3,"total_display":"4,356.30","shares_owned_after":125599.0,"shares_owned_after_display":"125,599","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-25","filed_date":"2020-11-30","scope":"insider"},{"id":2816184,"accession":"0001179110-20-006358","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-20-006358","line_url":"/filing/0001179110-20-006358#line-1","is_derivative":false,"issuer_cik":"0001130598","issuer_name":"Onconova Therapeutics, Inc.","issuer_ticker":"ONTX","issuer_name_source":null,"issuer_url":"/issuer/0001130598","owner_cik":"0001607714","owner_name":"Guerin Mark Patrick","owner_url":"/insider/0001607714","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21000.0,"shares_display":"21,000","price_per_share":0.36,"price_display":"0.36","price_state":"stated","total_value":7560.0,"total_display":"7,560.00","shares_owned_after":108844.0,"shares_owned_after_display":"108,844","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-19","filed_date":"2020-05-20","scope":"insider"},{"id":8310642,"accession":"0001179110-19-012056","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-19-012056","line_url":"/filing/0001179110-19-012056#line-1","is_derivative":false,"issuer_cik":"0001130598","issuer_name":"Onconova Therapeutics, Inc.","issuer_ticker":"ONTX","issuer_name_source":null,"issuer_url":"/issuer/0001130598","owner_cik":"0001607714","owner_name":"Guerin Mark Patrick","owner_url":"/insider/0001607714","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":87500.0,"shares_display":"87,500","price_per_share":0.2,"price_display":"0.20","price_state":"stated","total_value":17500.0,"total_display":"17,500.00","shares_owned_after":87844.0,"shares_owned_after_display":"87,844","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-25","filed_date":"2019-11-26","scope":"insider"},{"id":4968500,"accession":"0001179110-17-006249","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-17-006249","line_url":"/filing/0001179110-17-006249#line-1","is_derivative":false,"issuer_cik":"0001130598","issuer_name":"Onconova Therapeutics, Inc.","issuer_ticker":"ONTX","issuer_name_source":null,"issuer_url":"/issuer/0001130598","owner_cik":"0001607714","owner_name":"Guerin Mark Patrick","owner_url":"/insider/0001607714","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1429.0,"shares_display":"1,429","price_per_share":2.1,"price_display":"2.10","price_state":"stated","total_value":3000.9,"total_display":"3,000.90","shares_owned_after":5155.0,"shares_owned_after_display":"5,155","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-26","filed_date":"2017-04-28","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":6,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001130598","name":"Onconova Therapeutics, Inc.","url":"/issuer/0001130598","role":"Officer (Chief Financial Officer)","n_filings":5,"first_seen":"2017-04-28","last_seen":"2021-02-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001607714","retrieved_at":"2026-08-21T00:12:35+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}